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Purpose: The purpose of this study was to assess the ability of quantitative in vivo confocal microscopy (CM) to detect
changes in cystine crystal volume in the cystinosisn (Ctns−/−)mouse cornea following topical cysteamine therapy.
Methods: Fifteen Ctns−/− mice were sequentially followed using in vivo CM from 3 to 10 months of age. In a second
experiment, five mice receiving topical cysteamine eyedrops (0.55%) for 4 weeks were compared to five untreated mice.
The volume of corneal cystine crystals was determined by thresholding and counting high intensity pixels in the in vivo
CM scans and dividing by the stromal volume to calculate a crystal volume index (CVI).
Results: Corneal crystals progressively increased in density with age, reaching a peak density at 6–8 months and showing
a 70 fold increase in CVI. Eyes treated with cysteamine drops showed significantly less crystal accumulation compared
to control eyes (p<0.001) with only a 15% increase in treated eyes (p=ns) compared to 173% increase (p<0.04) for untreated
eyes.
Conclusions: Measurement of CVI shows that there is a progressive increase in cystine crystal volume up to 8 months
of age and that cysteamine eyedrops significantly inhibits progression in the Ctns−/− mouse. These findings are similar to
those seen clinically in patients with cystinosis, and suggest that measurement of CVI in the Ctns−/− mouse may be used
as a model to develop novel therapeutic strategies for treating corneal cystinosis.
Cystinosis is an autosomal recessive disease caused by a
mutation  in  the  lysosomal  membrane  transport  gene,
cystinosin  (CTNS)  located  on  chromosome  17p13  [1-5].
Accumulation of cystine in lysosomes leads to formation of
cystine crystals in various tissues and organs, including the
kidney,  muscle,  thyroid,  brain  and  eye  [5-11].  Different
CTNS  mutations  are  associated  with  varying  degrees  of
disease severity, with patients categorized into one of three
severity groups based on their age of onset and symptoms
[2]. The most severe form of the disease, infantile cystinosis,
results from the complete lack of cystine lysosomal transport,
with end-stage renal disease by age 10 [6,12].
Corneal cystine crystals appear within the first 16 months
of life, increase linearly during the first decade until they
plateau  in early  adolescence  [3,4,9-11].  The non-nephrop-
athic  forms of cystinosis (juvenile  and ocular cystinosis)
demonstrate  some residual  membrane  transport  function
and   are   associated   with  later  onset   and   more  limited
systemic manifestations. However, corneal crystals are also
present on these less severe forms of the disease [13,14].
Oral administration of cysteamine (HS-CH2-CH2-NH3)
or β-mercaptoethylamine has been the mainstay of cystinosis
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the  single  sulfide  amino  acid  cysteine,  plus  a  cysteine-
cysteamine mixed disulfide that exits the lysosome via the
lysine  transporter.  By  circumventing  the  cystinosin
transporter  defect  [18],  oral  cysteamine  has  significantly
improved overall prognosis [5,12,19,20]. However, systemic
administration  of  cysteamine  has  no  effect  on  corneal
cystinosis [6,21-23] because of inadequate local cysteamine
concentrations  [19].  Thus,  cysteamine  eyedrops  must  be
applied to the ocular surface at hourly intervals to achieve
sufficient drug concentrations to reduce corneal cystine levels.
While  this  treatment  strategy  is  been  shown  partially
successful, the drug dosing regimen is overly burdensome and
patient compliance is poor leaving many patients to suffer
from the chronic effects of corneal cystinosis.
Recently, a cystinosis (Ctns−/−) knockout mouse has been
generated  that  shows  development  of  cystine  crystals  in
multiple tissues and organs, including the cornea [24-27].
Although  the  Ctns−/−  mouse  does  not  under  go  proximal
tubulopathy  in  the  kidney,  quantitative  studies  of  organ
function indicate that kidney and eye function progressively
decrease with age indicating that the Ctns−/− mouse model
mimics disease progression seen clinically and is therefore a
potential  model  to  study  novel  therapeutic  strategies  for
treating human cystinosis [25,28-30].
We have recently developed a quantitative method to
evaluate corneal cystine crystal volume using in vivo confocal
microscopy (CM) to assess progression of corneal cystinosis
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therapy since 1994, when Cystagon™ was approved by the
USA FDA [15-17]. Cysteamine reacts with cystine to producein the Ctns−/− mouse model [31]. Our studies showed that
cystine crystals in the mouse cornea were first detected at 3
months of age in the posterior stroma/corneal endothelium
and that crystal volume progressively increased over time up
to  7  months  of  age,  followed  by  stromal  inflammation,
decreased stromal cell density and corneal scarring by 8–12
months  of  age.  In  the  present  study,  we  evaluated  the
sensitivity of using in vivo CM to measure temporal changes
in corneal cystine crystal volume to detect the effectiveness
of standard topical cysteamine therapy.
METHODS
Mice: A total of 25 Ctns−/− knockout mice were used in this
study. Fifteen Ctns−/− mice were followed and examined over
time at each of the following time points: 3, 4, 6, 8, and 10
months,  respectively.  At  each  time  point,  animals  were
anesthetized with intraperitoneal injections of ketamine HCl
(100 mg/Kg bodyweight; Bioniche Pharma, Lake Forest, IL)
and xylazine (20 mg/Kg bodyweight; Lloyd Laboratories,
Shenandoah, IO) and in vivo confocal microscopy (CM) was
used to assess the presence and location of cystine crystals. At
10  months  of  age,  animals  were  sacrificed  by  cervical
dislocation under anesthesia.
Ten 5 month old, Ctns−/− knockout mice were used to
measure the changes in the crystal volume after treating with
0.55% cysteamine eyedrops (Leiter's Pharmacy, San Jose,
CA)  for  4  weeks.  Briefly,  5  animals  were  treated  with
cysteamine eyedrops in both eyes, four times a day, while 5
animals were used as controls. Before and after treatment,
animal corneas were scanned using in vivo CM to assess the
presence and location of cystine crystals. Animals were then
sacrificed  by  cervical  dislocation  after  anesthesia.  All
procedures were approved by the UCI IACUC and conducted
in accordance with ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research.
In vivo confocal microscopy: Animals underwent in vivo CM
scanning  using  a  tandem  scanning  confocal  microscope
(TSCM; Tandem Scanning Corporation, Reston, VA) with a
24×  surface-contact  objective  (numerical  aperture,  0.6;
working distance, 1.5 mm), encoder mike controller (Oriel
18011; Oriel, Stratford, CT) for focal plane control, and a low
light level camera (MTI VE-1000; Dage MTI, Michigan City,
Figure 1. Confocal images of Ctns-\- mouse cornea. Confocal images of the same Ctns−/− cornea over time at 3 months (A), 6 months (B), 8
months (C), and 10 months of age (D). Each panel shows a xy (upper) slice through a 3D stack. Cystine crystals were identified as small, 20
µm long, needle-like crystals in the peripheral and central cornea. Note that cystine crystals increase progressively in quantity up to 8 months
of age (A, B, and C), but at 10 months, the cornea scarred and showed increased opacity.
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Irvine, CA) was placed on the tip of the objective as a coupling
gel. All camera settings were kept constant throughout the
experiment. For each eye, repeated data sets were obtained
from select central and peripheral corneal locations. Three to
five  through-focus  data  sets  were  collected  around  these
regions  for  assessment  of  cystine  crystal  volume  using
Metamorph  Image  Analysis  software  (Molecular  Devices,
Downingtown, PA).
Quantitative  assessment  of  cystine  crystal  content:  To
measure the cystine crystal content in the cornea, through
focus image data sets were analyzed by Metamorph Image
Processing  Software  (Molecular  Devices).  Initially,  the
stromal regions were extracted from the through focus data
set and then thresholded using the Threshold subroutine to
include all high intensity pixels representing light scattering
from  the  cystine  crystals.  Threshold  regions  were  set  to
include pixels intensity from 100 to 255. Pixels within the
threshold  region  were  then  counted  using  the  Measure
subroutine for all planes in the image stack to record the
crystal volume. To calculate a Percent Crystal volume Index
(CVI),  the  crystal  volume  was  divided  by  the  extracted
stromal volume multiplied by 100.
Statistical analysis: Each eye was considered independently
and results were reported as the mean±standard deviation
(SD). Differences over time and between treatment groups
were assessed by two-way repeated-measures ANOVA and
Bonferroni multiple comparisons (Sigma Stat version 3.11;
Systat Software Inc., Point Richmond, CA).
RESULTS
Progression of corneal cystinosis in the Ctns−/− mouse: A total
of 15 Ctns−/− mice were examined and followed using serial
in vivo CM. Seven animals died at different time points during
the course of the study and were excluded from the analysis.
Using in vivo CM, a few cystine crystals were detected at 3
months of age (Figure 1A) with increasing crystal volume up
to 6 to 8 months of age (Figure 1B,C respectively). Crystals
first  appeared  in  the  peripheral  posterior  stroma/corneal
endothelium and then progressed anteriorly and centrally with
age. By 10 months, Ctns−/− mouse corneas showed breakdown
of cystine crystals combined with corneal neovascularization,
fibrosis, and scarring (Figure 1D).
Table 1 and Figure 2 summarize the time-course changes
of the crystal volume index (CVI) of all the evaluated eyes,
excluding animals removed from the study. In this group, 4
eyes reached the highest CVI at 6 months averaging 2.9%
±0.94, 8 eyes reached the highest content of crystals at 8
months of age with an average CVI of 2.15%±1.04 and 2 eyes
showed a progressive increase in the CVI that peaked at 10
months  of  age.  Overall,  the  maximum  increase  in  crystal
deposition was from 3 to 8 months with an average 70 fold
increase  that  was  followed  by  decreasing  volume  due
presumably to corneal inflammation, neovascularization and
scarring.
A total of four out of the 16 eyes developed corneal
scaring by 10 months of age. Within this group, one eye was
already scarred at the time of the first scan at 3 months and
was not used to calculate change in crystal volume with age
in this study. Of the remaining 3 eyes, one eye developed
corneal scarring at 4 months and 2 eyes showed scarring at 10
month of age. These eyes were not included in the calculation
of  crystal  volume  at  later  time  points,  following  the
development of corneal scarring.
It is interesting to observe the asymmetry of the crystal
deposition  in  the  same  animal  suggesting  that  each  eye
TABLE 1. CRYSTAL VOLUME INDEX (CVI) TIME COURSE IN STUDY CORNEAS.
Eye ID 3 months 4 months 6 months 8 months 10 months
197OD 0 0.31 1.31 2.64 2.22
197 OS 0 0.68 1.68 2.13 0.45
198 OD SCAR SCAR SCAR SCAR SCAR
198 OS 0 0.38 1.38 2.41 0.88
176 OD 0 0.54 3.07 2.15 1.09
176 OS 0 0.36 4.18 1.89 SCAR
177 OD 0 0.08 2.06 1.34 0.51
177 OS 0.03 0.27 0.80 1.33 SCAR
178 OD 0 0.13 0.75 1.35 0.53
178 OS 0 0.13 0.30 1.34 1.53
194 OD 0.03 0.05 1.21 1.33 1.36
194 OS 0 0.29 1.09 1.54 0.87
195 OD 0 0.11 1.68 4.40 0.41
195 OS 0 0.32 2.35 1.86 SCAR
196 OD 0.33 SCAR SCAR SCAR SCAR
196 OS 0 0.15 0.91 1.44 1.13
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independently.  In  general,  eyes  showed  increased  crystal
volume from 3 to 4 months and 4 to 6 months of age. Over
70% of eyes (10/14) showed increased crystal volume from 6
to 8 months, while only 14% of eyes (2/14) showed increased
crystal volume from 8 to 10 months of age. Overall, these
findings suggest that the optimal age to evaluate the effects of
therapy on corneal cystine crystal formation using in vivo CM
should be from 3 to 6 months of age.
Effects of cysteamine eyedrops on corneal cystinosis: After
baseline, two eyes from the untreated group and one eye from
the  treated  group  showed  corneal  scarring  and  had  to  be
removed from the study. When comparing the remaining eyes
at baseline, there was no significant difference in the CVI
between untreated and treated groups, averaging 0.82% and
0.70% respectively (p=0.78; Table 2).
After 4 weeks, 2 eyes in the untreated group became
scarred and could not be evaluated for crystal deposition. The
remaining 6 eyes in the untreated group showed a significant
(173%) increase in the CVI (0.82% versus 1.41%, p≤0.04;
Table 2). By contrast, the cysteamine treated group showed
only a 15% increase in the CVI (from 0.70% before to 0.83%
after treatment, p=ns), significantly less than the untreated
group (p<0.0001). None of the eyes in the cysteamine treated
group  developed  scarring  after  treatment.  These  results
suggest  that  topical  cysteamine  eyedrops  delay  the
progression of corneal crystal deposition.
DISCUSSION
In this study, we have described a significant reduction in the
clinical progression of cystine crystal deposition in the Ctns−/
− mouse cornea with topical cysteamine. While the amount of
corneal crystals varied between animals, crystal deposition in
the  posterior  cornea  was  generally  noted  at  3  months.
Consistent with previous studies [28,31], a 70 fold increase in
crystal volume occurred between 3 months to 8 months of age
in untreated corneas, after which corneas became scarred.
Topical cysteamine eyedrops (applied 4 times daily for 4
weeks beginning at 5 months of age) significantly decreased
corneal crystal deposition compared to untreated Ctns−/− mice.
This data mirrors the response to topical cysteamine in
human  cystinosis,  where  substantial  clearance  of  cystine
Figure 2. Cystine crystal quantification
measured  as  the  percentage  (%)  of
crystals per stromal volume over time.
We observed a progressive increase in
the crystal content in corneas from 3 to
8 months of age. However, at 10 months
of  age,  crystal  volume  appeared  to
decrease due to breakdown of crystals
and/or  scarring.  A:  The  average  and
standard deviation values over time. B:
All  the  individual  eyes  that  were
followed over 10 months.
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While effective, topical cysteamine has several drawbacks,
including  poor  formulation  stability,  an  hourly  dosing
schedule and poor compliance (especially during childhood
and  adolescent  years)  [22,23,32].  To  overcome  these
shortcomings, drug development efforts have focused on the
development of formulations that reduce dosing frequency,
improve  compliance  and  quality  of  life  for  patients  with
corneal cystinosis of application [34,35]. These efforts can
potentially be accelerated using the Ctns−/− mouse model to
screen new therapeutic approaches before costly and time-
consuming human clinical trials.
ACKNOWLEDGMENTS
Supported  by  Cystinosis  Research  Foundation,  The
Discovery Eye Foundation, Research to Prevent Blindness,
Inc., and NEI grant EY016663.
REFERENCES
1. Anikster  Y,  Shotelersuk  V,  Gahl  WA.  CTNS  mutations  in
patients with cystinosis. Hum Mutat 1999; 14:454-8. [PMID:
10571941]
2. Attard M, Jean G, Forestier L, Cherqui S, van't Hoff W, Broyer
M, Antignac C, Town M. Severity of phenotype in cystinosis
varies with mutations in the CTNS gene: predicted effect on
the model of cystinosin. Hum Mol Genet 1999; 8:2507-14.
[PMID: 10556299]
3. Kalatzis V, Cohen-Solal L, Cordier B, Frishberg Y, Kemper M,
Nuutinen  EM,  Legrand  E,  Cochat  P,  Antignac  C.
Identification  of  14  novel  CTNS  mutations  and
characterization of seven splice site mutations associated with
cystinosis. Hum Mutat 2002; 20:439-46. [PMID: 12442267]
4. Shotelersuk V, Larson D, Anikster Y, McDowell G, Lemons R,
Bernardini I, Guo J, Thoene J, Gahl WA. CTNS mutations in
an American-based population of cystinosis patients. Am J
Hum Genet 1998; 63:1352-62. [PMID: 9792862]
5. Cantani A, Giardini O, D'Eufemia P. The treatment of cystinosis
with cysteamine. Ann Pediatr (Paris) 1991; 38:440. [PMID:
1929112]
6. Cantani  A,  Giardini  O,  Ciarnella  Cantani  A.  Nephropathic
cystinosis: ineffectiveness of cysteamine therapy for ocular
changes.  Am  J  Ophthalmol  1983;  95:713-4.  [PMID:
6846466]
7. Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI.
Corneal crystals in nephropathic cystinosis: natural history
and treatment with cysteamine eyedrops. Mol Genet Metab
2000; 71:100-20. [PMID: 11001803]
8. Gahl WA, Thoene JG, Schneider JA, O'Regan S, Kaiser-Kupfer
MI, Kuwabara T. NIH conference. Cystinosis: progress in a
prototypic  disease.  Ann  Intern  Med  1988;  109:557-69.
[PMID: 3048161]
9. Tsilou E, Zhou M, Gahl W, Sieving PC, Chan CC. Ophthalmic
manifestations and histopathology of infantile nephropathic
cystinosis: report of a case and review of the literature. Surv
Ophthalmol 2007; 52:97-105. [PMID: 17212992]
TABLE 2. CRYSTAL VOLUME INDEX (CVI) IN UNTREATED AND CYSTEAMINE TREATED EYES. 
Eye ID CVI at baseline (Mean±SD) CVI after treatment (Mean±SD) % change
Untreated
246 OD SCAR SCAR SCAR
246 OS 0.76±0.13 SCAR SCAR
247 OD 0.44±0.06 SCAR SCAR
247 OS 0.41±0.15 1.77±0.52 336
275 OD 0.25±0.06 0.40±0.07 61
275 OS 0.24±0.03 0.93±0.18 283
156 OD SCAR SCAR SCAR
156 OS 3.48±0.32 3.92±0.59 12
277 OD 0.46±0.26 0.78±0.45 67
277 OS 0.53±0.27 0.67±0.39 25
Mean CVI 0.82 1.41 173%
Cysteamine treated
276 OD 0.38±0.13 0.41±0.17 9
276 OS 0.77±0.40 0.60±0.19 -21
278 OD 0.43±0.09 0.49±0.08 16
278 OS 0.48±0.01 0.37±0.17 -22
279 OD 0.25±0.15 0.60±0.13 137
279 OS 0.17±0.11 0.28±0.13 65
249 OS 0.82±0.26 0.73±0.01 -10
249 OD 2.45±0.53 1.13±0.55 -53
245 OD 0.55±0.17 2.87±2.32 416
245 OS SCAR SCAR SCAR
Mean CVI 0.70 0.83 15%
Molecular Vision 2011; 17:2649-2654 <http://www.molvis.org/molvis/v17/a286> © 2011 Molecular Vision
265310. Tsilou ET, Rubin BI, Reed G, Caruso RC, Iwata F, Balog J,
Gahl  WA,  Kaiser-Kupfer  MI.  Nephropathic  cystinosis:
posterior segment manifestations and effects of cysteamine
therapy.  Ophthalmology  2006;  113:1002-9.  [PMID:
16603246]
11. Tsilou ET, Rubin BI, Reed GF, Iwata F, Gahl W, Kaiser-Kupfer
MI.  Age-related  prevalence  of  anterior  segment
complications  in  patients  with  infantile  nephropathic
cystinosis. Cornea 2002; 21:173-6. [PMID: 11862089]
12. Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB,
Jonas  AJ,  Denman  DW,  Schlesselman  JJ,  Corden  BJ,
Schneider  JA.  Cysteamine  therapy  for  children  with
nephropathic  cystinosis.  N  Engl  J  Med  1987;  316:971-7.
[PMID: 3550461]
13. Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med
2002; 347:111-21. [PMID: 12110740]
14. Iwata F, Kaiser-Kupfer MI. Ocular manifestations of metabolic
disorders.  Curr  Opin  Ophthalmol  1994;  5:79-83.  [PMID:
10150832]
15. Gahl  WA.  Early  oral  cysteamine  therapy  for  nephropathic
cystinosis.  Eur  J  Pediatr  2003;  162:S38-41.  [PMID:
14610675]
16. Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults:
natural history and effects of oral cysteamine therapy. Ann
Intern Med 2007; 147:242-50. [PMID: 17709758]
17. Kleta R, Gahl WA. Pharmacological treatment of nephropathic
cystinosis with cysteamine. Expert Opin Pharmacother 2004;
5:2255-62. [PMID: 15500372]
18. Thoene JG, Oshima RG, Crawhall JC, Olson DL, Schneider JA.
Cystinosis. Intracellular cystine depletion by aminothiols in
vitro  and  in  vivo.  J  Clin  Invest  1976;  58:180-9.  [PMID:
932205]
19. Tsilou ET, Thompson D, Lindblad AS, Reed GF, Rubin B, Gahl
W, Thoene J, Del Monte M, Schneider JA, Granet DB, Kaiser-
Kupfer MI. A multicentre randomised double masked clinical
trial  of  a  new  formulation  of  topical  cysteamine  for  the
treatment  of  corneal  cystine  crystals  in  cystinosis.  Br  J
Ophthalmol 2003; 87:28-31. [PMID: 12488257]
20. Markello  TC,  Bernardini  IM,  Gahl  WA.  Improved  renal
function in children with cystinosis treated with cysteamine.
N Engl J Med 1993; 328:1157-62. [PMID: 8455682]
21. Hsuan JD, Harding JJ, Bron AJ. The penetration of topical
cysteamine into the human eye. J Ocul Pharmacol Ther 1996;
12:499-502. [PMID: 8951686]
22. Jones NP, Postlethwaite RJ, Noble JL. Clearance of corneal
crystals  in  nephropathic  cystinosis  by  topical  cysteamine
0.5%. Br J Ophthalmol 1991; 75:311-2. [PMID: 2036352]
23. Kaiser-Kupfer MI, Fujikawa L, Kuwabara T, Jain S, Gahl WA.
Removal  of  corneal  crystals  by  topical  cysteamine  in
nephropathic  cystinosis.  N  Engl  J  Med  1987;  316:775-9.
[PMID: 3821824]
24. Cherqui  S,  Kalatzis  V,  Forestier  L,  Poras  I,  Antignac  C.
Identification and characterisation of the murine homologue
of the gene responsible for cystinosis, Ctns. BMC Genomics
2000; 1:2. [PMID: 11121245]
25. Cherqui S, Sevin C, Hamard G, Kalatzis V, Sich M, Pequignot
MO, Gogat K, Abitbol M, Broyer M, Gubler MC, Antignac
C.  Intralysosomal  cystine  accumulation  in  mice  lacking
cystinosin, the protein defective in cystinosis. Mol Cell Biol
2002; 22:7622-32. [PMID: 12370309]
26. Forestier L, Jean G, Attard M, Cherqui S, Lewis C, van't Hoff
W,  Broyer  M,  Town  M,  Antignac  C.  Molecular
characterization  of  CTNS  deletions  in  nephropathic
cystinosis: development of a PCR-based detection assay. Am
J Hum Genet 1999; 65:353-9. [PMID: 10417278]
27. Kalatzis V, Cherqui S, Antignac C, Gasnier B. Cystinosin, the
protein defective in cystinosis, is a H(+)-driven lysosomal
cystine  transporter.  EMBO  J  2001;  20:5940-9.  [PMID:
11689434]
28. Kalatzis  V,  Serratrice  N,  Hippert  C,  Payet  O,  Arndt  C,
Cazevieille C, Maurice T, Hamel C, Malecaze F, Antignac C,
Muller A, Kremer EJ. The ocular anomalies in a cystinosis
animal model mimic disease pathogenesis. Pediatr Res 2007;
62:156-62. [PMID: 17597652]
29. Kalatzis V, Cherqui S, Jean G, Cordier B, Cochat P, Broyer M,
Antignac C. Characterization of a putative founder mutation
that accounts for the high incidence of cystinosis in Brittany.
J Am Soc Nephrol 2001; 12:2170-4. [PMID: 11562417]
30. Kalatzis  V,  Nevo  N,  Cherqui  S,  Gasnier  B,  Antignac  C.
Molecular  pathogenesis  of  cystinosis:  effect  of  CTNS
mutations  on  the  transport  activity  and  subcellular
localization  of  cystinosin.  Hum  Mol  Genet  2004;
13:1361-71. [PMID: 15128704]
31. Simpson  J,  Nien  CJ,  Flynn  KJ,  Cherqui  S,  Jester  JV.
Quantitative in vivo and ex vivo confocal microscopy analysis
of corneal cystine crystals in the Ctns−/− knockout mouse.
Mol Vis 2011; 17:2212-20. [PMID: 21897743]
32. Kaiser-Kupfer MI, Gazzo MA, Datiles MB, Caruso RC, Kuehl
EM,  Gahl  WA.  A  randomized  placebo-controlled  trial  of
cysteamine  eye  drops  in  nephropathic  cystinosis.  Arch
Ophthalmol 1990; 108:689-93. [PMID: 2185723]
33. MacDonald IM, Noel LP, Mintsioulis G, Clarke WN. The effect
of topical cysteamine drops on reducing crystal formation
within  the  cornea  of  patients  affected  by  nephropathic
cystinosis.  J  Pediatr  Ophthalmol  Strabismus  1990;
27:272-4. [PMID: 2246744]
34. Bozdağ S, Gumus K, Gumus O, Unlu N. Formulation and in
vitro  evaluation  of  cysteamine  hydrochloride  viscous
solutions for the treatment of corneal cystinosis. Eur J Pharm
Biopharm 2008; 70:260-9. [PMID: 18590953]
35. Buchan B, Kay G, Heneghan A, Matthews KH, Cairns D. Gel
formulations for treatment of the ophthalmic complications
in  cystinosis.  Int  J  Pharm  2010;  392:192-7.  [PMID:
20382212]
Molecular Vision 2011; 17:2649-2654 <http://www.molvis.org/molvis/v17/a286> © 2011 Molecular Vision
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China.
The print version of this article was created on 4 October 2011. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
2654